aTyr Pharma (ATYR) Price & Analysis

Compare

2,835 Followers

ATYR Stock Chart & Stats

$0.76

-$0.23(-5.91%)

At close: Jan 08 4:00 PM EST

$0.76

-$0.23(-5.91%)

Day’s Range― - ―

52-Week Range$0.64 - $7.29

Previous CloseN/A

Volume346.43K

Average Volume (3M)3.12M

Market Cap

$79.20M

Enterprise Value-$7.95M

Total Cash (Recent Filing)$90.20M

Total Debt (Recent Filing)$12.36M

Price to Earnings (P/E)―

Beta0.99

Next Earnings

Mar 12, 2026

EPS Estimate

-0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding97,986,630

10 Day Avg. Volume1,788,277

30 Day Avg. Volume3,120,707

Financial Highlights & Ratios

PEG Ratio0.49

Price to Book (P/B)3.84

Price to Sales (P/S)1143.94

P/FCF Ratio-3.89

Enterprise Value/Market Cap-0.10

Enterprise Value/Revenue-41.83

Enterprise Value/Gross Profit0.23

Enterprise Value/Ebitda0.10

Forecast

1Y Price Target

$5.75

Price Target Upside656.58% Upside

Rating ConsensusHold

Number of Analyst Covering8

EPS Forecast (FY)-0.81

Revenue Forecast (FY)$106.36K

Bulls Say, Bears Say

Bulls Say

Clinical DataThe Phase 2 EFZO-CONNECT study shared positive interim data, showing encouraging early signals in patients with SSc-ILD.

Drug EfficacyThere is potential for accelerated approval with the current data package for efzofitimod.

Regulatory ApprovalsThe upcoming FDA meeting is considered a critical catalyst to determine whether there is a viable path forward for efzofitimod.

Bears Say

Analyst RecommendationsAnalyst is downgrading to HOLD until there is a clear decision on the path forward.

Clinical Trial ResultsThe EFZO-FIT study not meeting its primary endpoint clouds the regulatory and commercial path for efzofitimod.

Market SentimentThe stock is currently trading around a cash value of $1.02 per share and could see further pullback if there is no clear decision on the fate of the programs soon.

aTyr Pharma News

aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns

A class action lawsuit was filed against aTyr Pharma ($ATYR) on October 9, 2025. The plaintiffs (shareholders) alleged that they bought...

18d ago

ATYR

aTyr Pharma Receives Nasdaq Deficiency Notice

aTyr Pharma ( ($ATYR) ) has issued an announcement. On December 4, 2025, aTyr Pharma, Inc. received a...

8d ago

ATYR

aTyr Pharma Reports Increased Losses Amid Rising R&D Costs

Atyr Pharma Inc. ( ($ATYR) ) has released its Q3 earnings. Here is a breakdown of the information...

29d ago

ATYR

aTyr Pharma reports Q3 EPS (26c), consensus (18c)

“In September, we announced results from our Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis, a major...

1M ago

ATYR

aTyr Pharma Inc options imply 21.3% move in share price post-earnings

Pre-earnings options volume in aTyr Pharma (ATYR) Inc is normal with calls leading puts 3:2. Implied volatility suggests...

1M ago

ATYR

ATYR Earnings this Week: How Will it Perform?

Atyr Pharma Inc. (ATYR) is scheduled to report 3rd quarter earnings on 11/06/2025. Regarding Q3 estimates, Wall Street...

1M ago

ATYR

Atyr Pharma’s Promising Study on Efzofitimod for SSc-ILD: Key Insights for Investors

Atyr Pharma Inc. (($ATYR)) announced an update on their ongoing clinical study. Study Overview: Atyr Pharma Inc. is...

2M ago

ATYR

Symbotic, Serve Robotics, AeroVironment, aTyr Pharma, Cummins: Insider Moves Unveiled

Insiders have been trading these 5 stocks: (($SYM)), (($SERV)), (($AVAV)), (($ATYR)) and (($CMI)). Here is a breakdown of...

2M ago

CMI

SYM

aTyr Pharma Faces Legal Storm After Trial Failure

In a dramatic turn of events, aTyr Pharma, Inc. finds itself at the center of a class action...

2M ago

ATYR

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: YieldMax NVDA Option Income...

2M ago

HTZ

KDK

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Upexi (UPXI) 763.59% +160.80,...

2M ago

FIG

ATYR

Cautious Hold Rating for aTyr Pharma Amid Mixed Clinical Trial Results and Regulatory Uncertainty

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on ATYR stock, giving a Hold rating on...

2M ago

ATYR

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Proshares Bitcoin ETF (BITO)...

2M ago

NFE

ATYR

aTyr Pharma reports clinical benefit for efzofitimod across multiple diseases

aTyr Pharma (ATYR) presented additional findings from the Phase 3 EFZO-FIT study of efzofitimod in 268 patients with...

2M ago

ATYR

ATYR FAQ

What was aTyr Pharma’s price range in the past 12 months?

aTyr Pharma lowest stock price was $0.64 and its highest was $7.29 in the past 12 months.

What is aTyr Pharma’s market cap?

aTyr Pharma’s market cap is $79.20M.

When is aTyr Pharma’s upcoming earnings report date?

aTyr Pharma’s upcoming earnings report date is Mar 12, 2026 which is in 89 days.

How were aTyr Pharma’s earnings last quarter?

aTyr Pharma released its earnings results on Nov 06, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.184 by -$0.076.

Is aTyr Pharma overvalued?

According to Wall Street analysts aTyr Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does aTyr Pharma pay dividends?

aTyr Pharma does not currently pay dividends.

What is aTyr Pharma’s EPS estimate?

aTyr Pharma’s EPS estimate is -0.18.

How many shares outstanding does aTyr Pharma have?

aTyr Pharma has 97,986,630 shares outstanding.

What happened to aTyr Pharma’s price movement after its last earnings report?

aTyr Pharma reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.184. Following the earnings report the stock price went up 6.494%.

Which hedge fund is a major shareholder of aTyr Pharma?

Currently, no hedge funds are holding shares in ATYR

aTyr Pharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-103.22%

Trailing 12-Months

Asset Growth

16.41%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

aTyr Pharma

aTyr Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for rare diseases and immunological disorders. The company operates primarily in the biotechnology sector and is known for its proprietary platform that leverages naturally occurring proteins to create targeted treatments. aTyr's lead product candidates are based on its research into the physiological role of tRNA synthetases and their potential therapeutic applications, particularly in the fields of neuromuscular and pulmonary diseases.

aTyr Pharma (ATYR) Earnings & Revenues

Historic Earnings Reports

ATYR Stock 12 Month Forecast

Average Price Target

$5.75

▲(656.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","21":"$21","-1":"-$1","4.5":"$4.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4.5,10,15.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.74,2.2215384615384615,3.7030769230769236,5.184615384615386,6.666153846153847,8.147692307692308,9.629230769230771,11.110769230769233,12.592307692307694,14.073846153846155,15.555384615384616,17.036923076923078,18.51846153846154,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.74,1.1253846153846154,1.5107692307692306,1.896153846153846,2.2815384615384615,2.666923076923077,3.052307692307692,3.4376923076923074,3.823076923076923,4.208461538461538,4.593846153846154,4.979230769230769,5.364615384615385,{"y":5.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.74,0.76,0.78,0.8,0.82,0.84,0.86,0.88,0.9,0.9199999999999999,0.94,0.96,0.98,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.69,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >